Apellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating “that SYFOVRE is a clinically meaningful treatment” for the disease.
Read More
Apellis issues safety update after rare real-world retinal vasculitis reports
An investigation into rare events of retinal vasculitis linked to Apellis Pharmaceutical’s new therapy, SYFOVRE, for geographic atrophy (GA) has identified “internal structural variations” in a 19-gauge filter needle used to withdraw treatment from the vial.
Read More
Read More
IZERVAY Phase 3 clinical study achieves positive 24-month results
Astellas Pharma has announced positive 24-month topline results from the GATHER2 Phase 3 clinical study of IZERVAY, developed by its subsidiary Iveric Bio who recently secured regulatory approval in the US for the therapy.
Read More
Read More
Novartis discontinuing GT005 gene therapy clinical trial for geographic atrophy
Novartis will discontinue development of GT005 gene therapy, a subretinal injection for geographic atrophy (GA), in a blow to the global macular disease community, including Australia where the therapy was being trialled in some hospitals.
Read More
Read More
FDA approves Iveric Bio’s IZERVAY for geographic atrophy
The US Food and Drug Administration (FDA) has approved a second therapy for geographic atrophy (GA), with IZERVAY (avacincaptad pegol intravitreal solution) by Iveric Bio given clearance with its new complement C5 inhibitor.
Read More
Read More
Iveric Bio reveals vision loss reduction data in investigational geographic atrophy therapy
US biopharmaceutical company Iveric Bio has released new data for its avacincaptad pegol (ACP) therapy for geographic atrophy (GA), which showed up to a 59% risk reduction in rate of vision loss compared to sham treatment at 12 months.
Read More
Read More